Aurora Cannabis Inc
NASDAQ:ACB
Aurora Cannabis Inc
Aurora Cannabis, Inc. engages in the production, distribution and sale of cannabis products. The firm's principal business lines are focused on the production, distribution and sale of cannabis and cannabis related products in Canada and internationally. The firm's portfolio of brands includes Aurora, Aurora Drift, San Rafael '71, Daily Special, MedReleaf, CanniMed, Whistler, Reliva and KG7 CBD. Its cannabis products are primarily cultivated and manufactured in the facilities in Edmonton, Alberta; Bradford Ontario; Pemberton, British Columbia; and Odense, Denmark. The firm is focused on offering its cannabis products to global medical cannabis market, recreational cannabis market and global hemp-derived cannabidiol (CBD) markets. The company produces approximately 150,000 kilograms (kg) of cannabis biomass annually. Its subsidiaries include 1769474 Alberta Ltd., 2105657 Alberta Inc., Aurora Cannabis Enterprises Inc., Aurora Deutschland GmbH, Aurora Nordic Cannabis A/S, and Reliva, LLC, among others.
Aurora Cannabis, Inc. engages in the production, distribution and sale of cannabis products. The firm's principal business lines are focused on the production, distribution and sale of cannabis and cannabis related products in Canada and internationally. The firm's portfolio of brands includes Aurora, Aurora Drift, San Rafael '71, Daily Special, MedReleaf, CanniMed, Whistler, Reliva and KG7 CBD. Its cannabis products are primarily cultivated and manufactured in the facilities in Edmonton, Alberta; Bradford Ontario; Pemberton, British Columbia; and Odense, Denmark. The firm is focused on offering its cannabis products to global medical cannabis market, recreational cannabis market and global hemp-derived cannabidiol (CBD) markets. The company produces approximately 150,000 kilograms (kg) of cannabis biomass annually. Its subsidiaries include 1769474 Alberta Ltd., 2105657 Alberta Inc., Aurora Cannabis Enterprises Inc., Aurora Deutschland GmbH, Aurora Nordic Cannabis A/S, and Reliva, LLC, among others.
Revenue Growth: Aurora’s net revenue rose 11% to $90.4 million, driven by strong gains in global medical cannabis and international markets.
Margin Expansion: Adjusted gross margin improved by 700 basis points to 61%; medical cannabis margins reached a record 69%, exceeding targets.
Profitability: Adjusted EBITDA increased 52% to $15.4 million, outpacing revenue growth.
Cash Position: Aurora ended the quarter with $142 million in cash and no cannabis business debt.
Guidance: Management expects continued year-over-year revenue growth and positive free cash flow in Q3, led by 8–12% growth in global medical cannabis.
Canada Policy Watch: Potential changes to veterans' cannabis reimbursement are under review, but management cited uncertainty on impact.
International Strength: Aurora maintained or gained share in key medical cannabis markets including Canada, Germany, Poland and the U.K.
